News & Updates
Filter by Specialty:
Real-world study supports tralokinumab for difficult-to-treat AD
Interim data from the real-world TRACE study confirm the benefits of the high-affinity monoclonal antibody tralokinumab for individuals with moderate-to-severe head and neck atopic dermatitis (H&N AD) after up to 9 months of treatment.
Real-world study supports tralokinumab for difficult-to-treat AD
18 Oct 2024
Phototherapy for psoriasis at home as good as in the office
Narrowband ultraviolet B (NB-UVB) phototherapy or light therapy performed at home is as good as one done in the doctor’s office in patients with plaque and guttate psoriasis, as shown in the randomized Light Treatment Effectiveness (LITE) trial presented at EADV 2024.
Phototherapy for psoriasis at home as good as in the office
15 Oct 2024
Psoriasis patients with overweight, obesity may need higher vunakizumab dosage
In the treatment of moderate-to-severe psoriasis, patients with overweight or obesity appear to have a diminished response to vunakizumab compared with those who have lower BMIs, according to a post hoc subgroup analysis of a phase III trial.
Psoriasis patients with overweight, obesity may need higher vunakizumab dosage
14 Oct 2024
Ebdarokimab works wonders for patients with plaque psoriasis
A recent study has shown the safety and efficacy of AK 101 (ebdarokimab) in the treatment of patients with plaque psoriasis, achieving ≥75-percent improvement in Psoriasis Area and Severity Index (PASI 75) and Static Physicians Global Assessment (sPGA) 0/1 response.
